Authors

Jared Weiss, MD, UNC School of Medicine

Jared Weiss, MD, University of North Carolina School of Medicine

Jaron Mark, MD

Latest:

Dr. Mark Discusses an Ultra-Restrictive Opioid Prescription Protocol in Postoperative Patients

Jaron Mark, MD, gynecologic oncology fellow, Roswell Park Comprehensive Cancer Center, discusses the implementation of an ultra-restrictive opioid prescription protocol (UROPP) in patients undergoing major gynecologic surgery, which radically decreased dispensed opioids without reducing pain control, during the 2018 Society of Gynecologic Oncology Annual Meeting.

Jaroslaw P. Maciejewski, MD, PhD

Latest:

Dr. Maciejewski on Impact of Eltrombopag on Expansion of Clones in Refractory Aplastic Anemia

Jaroslaw P. Maciejewski, MD, PhD, chair, Department of Translational Hematology and Oncology Research, Cleveland Clinic, discusses the impact of eltrombopag on an expansion of clones with somatic mutations in patients with refractory aplastic anemia.

Jarrod Longcor, MS, MBA

Latest:

The Potential Utility of CLR 131 in Multiple Myeloma

Jarrod Longcor, MS, MBA, discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.

Jarushka Naidoo, MBBCh

Latest:

Looking at the Latest Data in Lung Cancer at ASCO 2023: Dr Naidoo

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins

Latest:

“Lung Cancer Talk”: A Review of Data from the ASCO 2020 Virtual Meeting

Jarushka Naidoo, MD, BCh

Latest:

Dr. Naidoo Discusses Biomarker Testing for Checkpoint Inhibitors

Jarushka Naidoo, MD, BCh, discusses the application of biomarker testing for use of checkpoint inhibitors in patients with cancer.

Jasgit Sachdev, MD

Latest:

Dr. Jasgit Sachdev on What's on the Horizon for Ovarian Cancer

Jasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses the goals she would like to see achieved regarding the treatment of ovarian cancer.

Jashodeep Datta, MD

Latest:

Camidge and Datta Detail the Career of an “Opportunistic Nomad”

Drs Camidge and Datta highlight Dr Datta’s career as a surgeon-scientist and research that aims to improve systemic therapies for pancreatic cancer.

Jasmeet C. Singh, MD

Latest:

Dr. Singh on Dose Dense ACTHP in HER2+ Breast Cancer

Jasmeet C. Singh, MD, discusses results from a retrospective analysis looking at the effectiveness of dose dense doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer.

Jasmine Kamboj, MD

Latest:

The Loss of My Friend

Every medical specialty is a unique subject, and oncology is no exception. Despite the vastness and depth that it entails, it resorts to some of the most universal laws of “being human.”

Jasmine M. Zain, MD

Latest:

Dr. Zain on Targets Under Investigation in T-Cell Lymphomas

Jasmine M. Zain, MD, hematologist/oncologist, associate clinical professor, Hematology and Hematopoietic Cell Transplantation, and director, T cell Lymphoma program, City of Hope, discusses targets that are under investigation in T-cell lymphomas.

Jasmine Rassiwala, MD

Latest:

Dr. Rassiwala on Results of "All-comers" Downstaging Protocol

Jasmine Rassiwala, MD, resident physician, University of California, San Francisco, discusses the analysis of the “all-comers” downstaging protocol, which investigated whether there were upper limits in tumor burden for successful downstaging of patients with hepatocellular carcinoma to liver transplant.

Jasmine Zain, MD

Latest:

Challenges With CAR T-Cell Therapies in T-Cell Lymphomas

Jasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.

Jason A. Konner, MD

Latest:

Dr. Konner on Preferred Platinum Doublets in Recurrent Ovarian Cancer

Jason A. Konner, MD, medical oncologist, Memorial Sloan Kettering Cancer, discusses preferred platinum doublet chemotherapies in the treatment of patients with recurrent ovarian cancer.

Jason Astrin, PA-C, MBA, DFAAPA

Latest:

A Collaborative Model for Advanced Practice Providers Empowers Success

The burden on oncologists is becoming unmanageable, leading many practices to turn to advanced practice providers.

Jason B. Fleming, MD

Latest:

Dr. Fleming on the KEYNOTE-426 Trial in Metastatic RCC

Mark T. Fleming, MD, discusses the phase 3 KEYNOTE-426 trial in advanced or metastatic renal cell carcinoma.

Jason Broderick

Latest:

First-Line Nivolumab/Chemo Generates Long-Term Survival Benefits in Gastric/GEJ/Esophageal Cancer

Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.

Jason D. Wright, MD

Latest:

Dr. Wright on Measuring Progression and Recurrence in Ovarian Cancer

Jason D. Wright, MD, Division Chief, Gynecologic Oncology, Associate Clinical Professor of Gynecologic Oncology, Sol Goldman Associate Professor of Obstetrics and Gynecology, Columbia University, discusses the challenges in measuring progression and recurrence in patients with ovarian cancer.